文献速递肝病

美国脂肪性肝病(MASLD、MetALD与ALD)患病率:NHANES 2017-2020

Prevalence of Steatotic Liver Disease (MASLD, MetALD, and ALD) in the United States: NHANES 2017-2020.
PubMed 文献 · Clin Gastroenterol Hepatol · 2023-11-08

研究利用美国国家代表性数据集NHANES 2017-2020计算脂肪性肝病(SLD)及其亚类在美国的患病率。文中介绍了德尔菲共识后SLD、MASLD和MetALD的新命名与定义,MetALD定义为女性每日饮酒20-50克(每周140-350克)、男性每日30-60克(每周210-420克)。

要点

  • SLD新命名旨在提高精确性并减少污名化。
  • MASLD取代NAFLD成为新术语。
  • MetALD涵盖饮酒量介于NAFLD阈值与过量之间的未分类人群。

核心结论

  • 研究使用美国国家代表性数据集计算SLD及其亚类在美国的患病率。

研究设计与样本

  • 研究使用美国国家代表性数据集(NHANES 2017-2020)计算患病率。

关键数值与推荐

  • MetALD定义为女性每日饮酒20至50克(或每周140-350克),男性每日30至60克(或每周210-420克)。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Following the Delphi consensus process, the term steatotic liver disease (SLD) was introduced to replace fatty liver disease, while the term metabolic dysfunction-associated steatotic liver disease (MASLD) emerged as the successor to the term nonalcoholic fatty liver disease (NAFLD).1 This revised nomenclature aims to enhance precision and mitigate negative connotations and potential stigmatization, while refining comprehension and disease categorization. Concurrently, a novel category was introduced to capture individuals whose alcohol consumption exceeded the previously defined thresholds of NAFLD but remained unclassified within the existing system. This category, termed MetALD, now delineates a spectrum of conditions and is defined as a daily intake of 20 to 50 g of alcohol (or weekly 140-350 g) for females and 30 to 60 g daily for males (or weekly 210-420 g).1 Within the MetALD spectrum, some individuals might predominantly exhibit MASLD characteristics, whereas others might be more inclined toward alcoholic liver disease (ALD).1 In the present study, we used a US nationally representative data set to calculate the prevalence of SLD and its subcategories in the United States.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Kalligeros M, Vassilopoulos A, Vassilopoulos S, et al. Prevalence of Steatotic Liver Disease (MASLD, MetALD, and ALD) in the United States: NHANES 2017-2020. Clin Gastroenterol Hepatol. 2023. PMID: 37949334. doi:10.1016/j.cgh.2023.11.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。